Visualization Analysis of Research Hotspots and Trends in Field of Tumor Therapy Based on CiteSpace and VOSviewer

FANG Yuhang; ZHANG Chuchu; SUI Bailu; WANG Yan; WANG Runxi; CHEN Yu; YUAN Xinhe; YANG Hongjun; ZHANG Ying

doi:10.3971/j.issn.1000-8578.2025.24.0959

Cancer Research on Prevention and Treatment > 2025 > 52(4): 297-304. > DOI: 10.3971/j.issn.1000-8578.2025.24.0959

FANG Yuhang, ZHANG Chuchu, SUI Bailu, WANG Yan, WANG Runxi, CHEN Yu, YUAN Xinhe, YANG Hongjun, ZHANG Ying. Visualization Analysis of Research Hotspots and Trends in Field of Tumor Therapy Based on CiteSpace and VOSviewer[J]. Cancer Research on Prevention and Treatment, 2025, 52(4): 297-304. DOI: 10.3971/j.issn.1000-8578.2025.24.0959

Citation:

PDF (7433 KB)

Visualization Analysis of Research Hotspots and Trends in Field of Tumor Therapy Based on CiteSpace and VOSviewer

FANG Yuhang^{1, 2, ,},
ZHANG Chuchu^3,,
SUI Bailu^{1, 2,},
WANG Yan^1,,
WANG Runxi^1,,
CHEN Yu^{1, 2,},
YUAN Xinhe^{1, 2,},
YANG Hongjun^4,,
ZHANG Ying^1, , ,

1.
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
2.
Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China
3.
Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
4.
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China

Funding:

China Academy of Chinese Medical Sciences Soft Science Special Project – Strategic Research on Technological Breakthroughs in Traditional Chinese Medicine for the Prevention and Treatment of Major Chronic Diseases (No. ZZ17-RKX-01)

undefined

More Information

Corresponding author:
ZHANG Ying, E-mail: zylzy501@163.com
Received Date: September 28, 2024
Revised Date: February 15, 2025
Accepted Date: February 16, 2025
Available Online: February 26, 2025

Graphical Abstract

Abstract

Abstract

Objective
To explore the research hotspots and development trends in the field of cancer treatment in the past decade.
Methods
The CNKI and Web of Science Core Collection databases were searched for Chinese and English articles related to cancer treatment published over the last 10 years. Bibliometric research methods were employed, including keyword cluster analysis of published literature.
Results
A total of 45 455 Chinese articles and 866 958 English articles were retrieved. Combining the visualization analysis results and the current research dilemma of tumor treatment revealed that the current research hotspots of tumor treatment domestically and internationally can primarily focus on four key areas. In the realm of targeted therapy, efforts are directed towards the discovery of new drug targets, overcoming resistance to targeted therapy, and the development of monoclonal antibodies and antibody–drug conjugates. In the field of immunotherapy, the emphasis lies in enhancing the response rate to immune checkpoint inhibitors, determining the mechanisms behind resistance to immunotherapy, and improving the safety of treatment. The research in traditional Chinese medicine (TCM) covers evidence-based evaluation studies on TCM treatment, the identification of populations that can gain the most benefit from TCM, and strategies for improving the quality of life. In the area of novel drug development, cutting-edge technologies, such as organoid-based screening for anticancer drugs, synthetic biology, and artificial intelligence, are under investigation.
Conclusion
New targeted drugs, immune efficacy improvement, multidisciplinary integration, nano-delivery, and TCM innovation are the key research directions in the field of tumor therapy in the future.
- Tumor therapy,
- Targeted therapy,
- Immunotherapy,
- Traditional Chinese medicine therapy,
- New drug development and research,
- Bibliometrics

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (31)

References

[1]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. doi: 10.1016/j.jncc.2024.01.006
[2]	Steeg PS. Targeting metastasis[J]. Nat Rev Cancer, 2016, 16(4): 201-218. doi: 10.1038/nrc.2016.25
[3]	高峰, 刘徳军, 张宪伟, 等. 老年广泛期小细胞肺癌EP/EC方案化疗的疗效与安全性分析[J]. 实用医学杂志, 2020, 36(18): 2555-2558. [Gao F, Liu DJ, Zhang XW, et al. Efficacy and safety evaluation of EP/EC chemotherapy in elderly patients with extensive-stage small-cell lung cancer[J]. Shi Yong Yi Xue Za Zhi, 2020, 36(18): 2555-2558.] doi: 10.3969/j.issn.1006-5725.2020.18.020 Gao F, Liu DJ, Zhang XW, et al. Efficacy and safety evaluation of EP/EC chemotherapy in elderly patients with extensive-stage small-cell lung cancer[J]. Shi Yong Yi Xue Za Zhi, 2020, 36(18): 2555-2558. doi: 10.3969/j.issn.1006-5725.2020.18.020
[4]	刘丽桃, 谢妮, 郭文鹏. 纳米技术在乳腺癌化疗中的应用研究进展[J]. 癌变·畸变·突变, 2015, 27(1): 75-81. [Liu LT, Xie N, Guo WP. Research progress of nanotechnology in breast cancer chemotherapy[J]. Ai Bian·Ji Bian·Tu Bian, 2015, 27(1): 75-81.] Liu LT, Xie N, Guo WP. Research progress of nanotechnology in breast cancer chemotherapy[J]. Ai Bian·Ji Bian·Tu Bian, 2015, 27(1): 75-81.
[5]	Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review[J]. Lancet Oncol, 2019, 20(11): e619-e626. doi: 10.1016/S1470-2045(19)30491-7
[6]	Gowd V, Ahmad A, Tarique M, et al. Advancement of cancer immunotherapy using nanoparticles-based nanomedicine[J]. Semin Cancer Biol, 2022, 86 (Pt 2): 624-644.
[7]	Li G, Liu Y, Hu H, et al. Evolution of innovative drug R&D in China[J]. Nat Rev Drug Discov, 2022, 21(8): 553-554 doi: 10.1038/d41573-022-00058-6
[8]	Clara JA, Monge C, Yang Y, et al. Targeting signalling pathways and the immune microenvironment of cancer stem cells-a clinical update[J]. Nat Rev Clin Oncol, 2020, 17(4): 204-232. doi: 10.1038/s41571-019-0293-2
[9]	刘慧, 李丽, 刘洋汉, 等. 肿瘤相关巨噬细胞靶向治疗研究进展[J]. 广西师范大学学报(自然科学版), 2022, 40(5): 286-299. [Liu H, Li L, Liu YH, et al. Advances in Targeted Therapy of Tumor-Associated Macrophages[J]. Guangxi Shi Fan Da Xue Xue Bao (Zi Ran Ke Xue Ban), 2022, 40(5): 286-299.] Liu H, Li L, Liu YH, et al. Advances in Targeted Therapy of Tumor-Associated Macrophages[J]. Guangxi Shi Fan Da Xue Xue Bao (Zi Ran Ke Xue Ban), 2022, 40(5): 286-299.
[10]	张宏, 卜嘉文. 结直肠癌靶向治疗的耐药机制及潜在解决方案[J]. 中国实用外科杂志, 2024, 44(7): 774-780. [Zhang H, Bu JW. Drug resistance mechanisms of targeted therapy of colorectal cancer and potential solutions[J]. Zhongguo Shi Yong Wai Ke Za Zhi, 2024, 44(7): 774-780.] Zhang H, Bu JW. Drug resistance mechanisms of targeted therapy of colorectal cancer and potential solutions[J]. Zhongguo Shi Yong Wai Ke Za Zhi, 2024, 44(7): 774-780.
[11]	Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions[J]. Nat Rev Drug Discov, 2023, 22(2): 101-126. doi: 10.1038/s41573-022-00579-0
[12]	Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697. doi: 10.1016/S0140-6736(10)61121-X
[13]	李静, 伍玉琳, 马翠翠, 等. 抗体偶联药物的研究进展[J]. 华西药学杂志, 2023, 38(5): 586-592. [Li J, Wu YL, Ma CC, et al. Research progress on antibody-drug conjugates[J]. Hua Xi Yao Xue Za Zhi, 2023, 38(5): 586-592.] Li J, Wu YL, Ma CC, et al. Research progress on antibody-drug conjugates[J]. Hua Xi Yao Xue Za Zhi, 2023, 38(5): 586-592.
[14]	Fu Z, Li S, Han S, et al. Antibody drug conjugate: the "biological missile" for targeted cancer therapy[J]. Signal Transduct Target Ther, 2022, 7(1): 93. doi: 10.1038/s41392-022-00947-7
[15]	Memon D, Schoenfeld AJ, Ye D, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer[J]. Cancer Cell, 2024, 42(2): 209-224. e9.
[16]	Liu J, Fu M, Wang M, et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress[J]. J Hematol Oncol, 2022, 15(1): 28. doi: 10.1186/s13045-022-01247-x
[17]	何香川, 刘明斌, 张晓燕, 等. 靶向肿瘤微环境(TME)免疫治疗策略的研究进展[J]. 复旦学报(医学版), 2020, 47(1): 128-134. [He XC, Liu MB, Zhang XY, et al. The immunotherapeutic strategy for tumor microenvironment (TME)[J]. Fudan Xue Bao (Yi Xue Ban), 2020, 47(1): 128-134.] He XC, Liu MB, Zhang XY, et al. The immunotherapeutic strategy for tumor microenvironment (TME)[J]. Fudan Xue Bao (Yi Xue Ban), 2020, 47(1): 128-134.
[18]	全家乐, 康彦良, 张万里, 等. 肿瘤免疫治疗中过继性细胞疗法的研究进展[J]. 药学进展, 2021, 45(10): 725-734. [Quan JL, Kang YL, Zhang WL, et al. Advances in Research on Adoptive Cell Therapy in Tumor Immunotherapy[J]. Yao Xue Jin Zhan, 2021, 45(10): 725-734.] Quan JL, Kang YL, Zhang WL, et al. Advances in Research on Adoptive Cell Therapy in Tumor Immunotherapy[J]. Yao Xue Jin Zhan, 2021, 45(10): 725-734.
[19]	Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial[J]. Gut, 2018, 67(11): 2006-2016. doi: 10.1136/gutjnl-2018-315983
[20]	Chen L, Zhu HM, Li Y, et al. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)[J]. Proc Natl Acad Sci U S A, 2021, 118(6): e2020382118. doi: 10.1073/pnas.2020382118
[21]	Wang HY, Gong S, Li GH, et al. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)[J]. Blood Cancer J, 2022, 12(11): 158. doi: 10.1038/s41408-022-00753-y
[22]	Cheng X, Huo J, Wang D, et al. Herbal Medicine AC591 Prevents Oxaliplatin-Induced Peripheral Neuropathy in Animal Model and Cancer Patients[J]. Front Pharmacol, 2017, 8: 344. doi: 10.3389/fphar.2017.00344
[23]	Li Y, Gu J, Zhou H, et al. Traditional Chinese Medicine symptom patterns in patients with colorectal carcinoma[J]. J Tradit Chin Med, 2018, 38(2): 299-308. doi: 10.1016/j.jtcm.2018.03.004
[24]	苏春雨, 朱广辉, 李杰. 非小细胞肺癌术后患者症状分布规律及升陷汤加减的干预效果[J]. 中医杂志, 2020, 61(7): 601-606. [Su CY, Zhu GH, Li J. Symptoms Distribution Rules of Postoperative Non-small Cell Lung Cancer Patients and Intervention Effect of Modified Shengxian Decoction[J]. Zhong Yi Za Zhi, 2020, 61(7): 601-606.] Su CY, Zhu GH, Li J. Symptoms Distribution Rules of Postoperative Non-small Cell Lung Cancer Patients and Intervention Effect of Modified Shengxian Decoction[J]. Zhong Yi Za Zhi, 2020, 61(7): 601-606.
[25]	姚嘉麟, 赵艺, 焦丽静, 等. 益气养阴病证结合辨治肺癌表皮生长因子受体酪氨酸激酶抑制剂靶向治疗相关症状群的随机对照双盲临床研究[J]. 中华中医药杂志, 2023, 38(5): 2470-2476. [Yao JL, Zhao Y, Jiao LJ, et al. Effects of the herbal formula based on disease-syndrome combination of benefiting qi and nourishing yin treatment on symptom clusters associated with EGFR-TKI targeted therapy for lung cancer patients: A randomized, double-blind study[J]. Zhong Hua Zhong Yi Yao Za Zhi, 2023, 38(5): 2470-2476.] Yao JL, Zhao Y, Jiao LJ, et al. Effects of the herbal formula based on disease-syndrome combination of benefiting qi and nourishing yin treatment on symptom clusters associated with EGFR-TKI targeted therapy for lung cancer patients: A randomized, double-blind study[J]. Zhong Hua Zhong Yi Yao Za Zhi, 2023, 38(5): 2470-2476.
[26]	Li H, Ma C, Chang S, et al. Traditional Chinese Medicine Decoctions Improve Longevity Following Diagnosis with Stage Ⅳ Esophageal Squamous Cell Carcinoma: A Retrospective Analysis[J]. Int J Gen Med, 2022, 15: 1665-1675. doi: 10.2147/IJGM.S346536
[27]	张百红, 岳红云. 合成生物学和肿瘤治疗[J]. 现代肿瘤医学, 2023, 31(13): 2533-2536. [Zhang BH, Yue HY. Synthetic biology and cancer therapy[J]. Xian Dai Zhong Liu Yi Xue, 2023, 31(13): 2533-2536.] doi: 10.3969/j.issn.1672-4992.2023.13.031 Zhang BH, Yue HY. Synthetic biology and cancer therapy[J]. Xian Dai Zhong Liu Yi Xue, 2023, 31(13): 2533-2536. doi: 10.3969/j.issn.1672-4992.2023.13.031
[28]	Fang Z, Li P, Du F, et al. The role of organoids in cancer research[J]. Exp Hematol Oncol, 2023, 12(1): 69. doi: 10.1186/s40164-023-00433-y
[29]	管庆霞, 罗煜婷, 刘宇萌, 等. 人工智能在抗肿瘤药物研发中的应用与进展[J]. 中国现代应用药学, 2023, 40(23): 3318-3323. [Guan QX, Luo YT, Liu YM, et al. Application and Progress of Artificial Intelligence in Development of Anti-tumor Drugs[J]. Zhongguo Xian Dai Ying Yong Yao Xue, 2023, 40(23): 3318-3323.] Guan QX, Luo YT, Liu YM, et al. Application and Progress of Artificial Intelligence in Development of Anti-tumor Drugs[J]. Zhongguo Xian Dai Ying Yong Yao Xue, 2023, 40(23): 3318-3323.
[30]	Al RA, Chakma R, Dewan K, et al. Current advanced drug delivery systems: Challenges and potentialities[J]. J Drug Deliv Sci Technol, 2022, 76: 103727. doi: 10.1016/j.jddst.2022.103727
[31]	Henn JG, Aguirre TAS, Nugent M, et al. Cancer nanomedicine: Recent developments in drug delivery systems and strategies to overcome eventual barriers to achieve a better outcome[J]. J Drug Deliv Sci Technol, 2024, 91: 105254. doi: 10.1016/j.jddst.2023.105254

Cited By

Cited by

Periodical cited type(2)

1.	莫艳秀，姚飞虹，刘峻彤，胡紫昂，李木兰. SP600125对人宫颈癌HeLa细胞增殖和侵袭的影响. 肿瘤防治研究. 2022(04): 304-313 . 本站查看
2.	赵永，黄萍，郭子文，汪琼. 基于加权基因共表达网络分析慢性阻塞性肺疾病的差异基因及信号通路. 华南国防医学杂志. 2022(12): 959-966 .

Other cited types(2)

Figures(5) / Tables(5)

Get Citation

PDF

XML

Article views (994) PDF downloads (192) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Visualization Analysis of Research Hotspots and Trends in Field of Tumor Therapy Based on CiteSpace and VOSviewer